CARB-X IS FUNDING ACCELERATE DIAGNOSTICS TO DEVELOP A RAPID OPTICAL IMAGING DIAGNOSTIC FOR SEPSIS AND SERIOUS ANTIBIOTIC-RESISTANT BACTERIAL INFECTIONS

CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds.

Sepsis is the body’s overwhelming and life-threatening response to an infection that can lead to tissue damage, organ failure and death.  Speed is critical in diagnosing infections and sepsis. Each hour delay in the appropriate treatment of sepsis increases the chances of death.